Literature DB >> 8669813

Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours.

G Thiel1, K Marczinek, R Neumann, R Witkowski, D A Marchuk, P Nurnberg.   

Abstract

The increased frequency of glioma among neurofibromatosis 1 (NF1) patients suggests a general involvement of the NF1 gene in glioma tumourigenesis. Using the methodology of conventional Southern blotting with a complete panel of overlapping partial cDNAs covering the whole NF1 gene, we screened 31 gliomas of several different subtypes and 3 primitive neuroectodermal tumours (PNETs) from non-NF1 patients for aberrant restriction patterns in their tumour DNA samples. Clear evidence for somatic mutation events at the NF1 gene locus was found in 1 astrocytoma, 2 glioblastomas, 1 ependymoma and 1 PNET with an astrocytic component. These results suggest that the NF1 gene is important in suppressing tumours of neuroectodermal origin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8669813

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Unusual clustering of brain tumours in a family with NF1 and variable expression of cutaneous features.

Authors:  F Faravelli; M Upadhyaya; M Osborn; S M Huson; R Hayward; R Winter
Journal:  J Med Genet       Date:  1999-12       Impact factor: 6.318

Review 2.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Somatic deletion of the 5' ends of both the COL4A5 and COL4A6 genes in a sporadic leiomyoma of the esophagus.

Authors:  L Heidet; E Boye; Y Cai; Y Sado; X Zhang; J F Fléjou; F Fékété; Y Ninomiya; M C Gubler; C Antignac
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

4.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

Authors:  Lauren T McGillicuddy; Jody A Fromm; Pablo E Hollstein; Sara Kubek; Rameen Beroukhim; Thomas De Raedt; Bryan W Johnson; Sybil M G Williams; Phioanh Nghiemphu; Linda M Liau; Tim F Cloughesy; Paul S Mischel; Annabel Parret; Jeanette Seiler; Gerd Moldenhauer; Klaus Scheffzek; Anat O Stemmer-Rachamimov; Charles L Sawyers; Cameron Brennan; Ludwine Messiaen; Ingo K Mellinghoff; Karen Cichowski
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

Review 6.  Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.

Authors:  Hui-Wen Lo
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

7.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

8.  MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1.

Authors:  Michelle Lenarduzzi; Angela B Y Hui; Nehad M Alajez; Wei Shi; Justin Williams; Shijun Yue; Brian O'Sullivan; Fei-Fei Liu
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.